Trial Profile
A Phase 2, Open-Label, Multicenter, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF–Rho™ in Patients with Chronic Neutropenia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs Pegfilgrastim ANF (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Prolong Pharmaceuticals
- 12 Oct 2018 New trial record